Tag: targeted therapy
New Drug Daraxonrasib Nearly Doubles Pancreatic Cancer Survival in Phase 3 Trial
Daraxonrasib nearly doubles survival in advanced pancreatic cancer patients with KRAS G12C mutations. The breakthrough targets a previously "undruggable" protein…
New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial
A phase 2 trial published in NEJM shows promise for daraxonrasib, a novel targeted therapy for previously treated metastatic pancreatic…
Savolitinib Shows Promise for MET-Amplified Gastric Cancer in Phase 2 Trial
A phase 2 trial shows promising clinical efficacy for savolitinib in treating patients with MET-amplified gastric or gastroesophageal junction adenocarcinoma.…
Submit Your Paper to GMJ
No APC until January 2027.